Charlie's Q2 FY26 operating loss widens to $1.23 million; revenue more than doubled to $3.8 million
CHUC•Regulatory update and Q3 plans
The FDA flagged 30 PACHA SKUs for a “low-enforcement priority” list, while Charlie's plans an age-gated disposable test launch in Q3.
Losses widen as operating costs rise
Net loss widened to $1.66 million from net income a year earlier, when results included a $6.5 million gain on IP sales.
Operating loss widened to $1.23 million as total operating costs and expenses climbed 63.3% to $2.35 million.
Revenue more than doubles in Q2 FY26
Charlie's Holdings posted Q2 revenue of $3.8 million, more than doubled from a year earlier.
Gross profit rose to $1.12 million, while revenue growth was driven by higher nicotine-based and nicotine-alternative product sales, including SBX.
